← All trials
NCT05136599
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 17, 2022
- Primary completion
- Nov 11, 2022
- Completion date
- Nov 10, 2023
- First posted
- Nov 29, 2021
- Last posted
- Nov 29, 2021
- Enrollment
- 66
- Arms / groups
- 7 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Dalhousie UniversityLead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)Collaborator
- Dalhousie UniversityOverall official - principal investigator
- Vanderbilt UniversityCollaborator
- Centers for Disease Control and Prevention (CDC)Collaborator
- IntravaccCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.